Search results
Showing 256 to 270 of 1766 results for patient safety
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Ustekinumab for treating moderate to severe plaque psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)
Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.
In development Reference number: GID-TA11767 Expected publication date: 04 November 2026
In development Reference number: GID-TA11186 Expected publication date: TBC
Biographies for all current members of the diagnostics advisory committee.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.
This guideline covers managing cataracts in adults aged 18 and over. It aims to improve care before, during and after cataract surgery by optimising service organisation, referral and surgical management, and reducing complications. It further aims to improve the availability of information for people with cataracts before, during and after cataract surgery.
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.
Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NG1)
This guideline covers diagnosing and managing gastro-oesophageal reflux disease in children and young people (under 18s). It aims to raise awareness of symptoms that need investigating and treating, and to reassure parents and carers that regurgitation is common in infants under 1 year.
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Suspected neurological conditions: recognition and referral (QS198)
This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS198Show all sections
Sections for QS198
- Quality statements
- Quality statement 1: Headaches and 'red flag' symptoms in children
- Quality statement 2: Head size and shape in children
- Quality statement 3: Suspected dystonia in adults
- Quality statement 4: Hallpike manoeuvre for adults
- Quality statement 5: Functional neurological disorders in adults
- Quality statement 6: Individualised care for adults
- About this quality standard
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance